Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Activated charcoal + sorbitol** is an oral gastrointestinal decontamination combination used for emergency management of acute oral poisonings and toxic ingestions. Activated charcoal is a porous, non-systemically absorbed adsorbent that binds many drugs and toxins within the gastrointestinal lumen, reducing their systemic absorption. Sorbitol is an osmotic cathartic included to improve palatability and promote intestinal evacuation of the charcoal-toxin complex. The human product **Actidose with Sorbitol** is supplied as a ready-to-use oral suspension containing activated charcoal and sorbitol; the label specifies 25 g activated charcoal with 48 g sorbitol or 50 g activated charcoal with 96 g sorbitol. It should not be used in persons who are not fully conscious because of aspiration risk, and sorbitol-containing charcoal products are not recommended for multiple-dose charcoal therapy because excessive catharsis can cause clinically significant fluid and electrolyte abnormalities. ([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7da3506f-2799-434c-e053-2a91aa0adabb))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on activated charcoal + sorbitol.